PYC Advances Four Genetic-Disease Drug Programs, With Kidney Trial Data Expected Next Year
PYC: $1.93 -1.78% · MC: $1.9B
PYC Therapeutics reported progress across four drug programs, including advancing its Phelan-McDermid candidate into required toxicology studies and moving its kidney-disease candidate into higher-dose and longer-term studies. The company said data from the ongoing kidney studies is expected in 2027, while early exploratory results from a single-dose study were presented after the quarter.

Comments